Rahemtulla A - Search Results

1

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Grand EK, et al. Among authors: rahemtulla a. Leukemia. 2004 May;18(5):962-6. doi: 10.1038/sj.leu.2403347. Leukemia. 2004. PMID: 15029211

2

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.

Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Tornatore L, et al. Among authors: rahemtulla a. Cancer Cell. 2014 Oct 13;26(4):495-508. doi: 10.1016/j.ccr.2014.07.027. Cancer Cell. 2014. PMID: 25314077 Free PMC article.

3

Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.

Terpos E, Politou M, Viniou N, Rahemtulla A. Terpos E, et al. Among authors: rahemtulla a. Leuk Lymphoma. 2005 Dec;46(12):1699-707. doi: 10.1080/10428190500175049. Leuk Lymphoma. 2005. PMID: 16263571 Review.

4

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.

Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. Politou M, et al. Among authors: rahemtulla a. Leuk Res. 2006 Feb;30(2):240-1. doi: 10.1016/j.leukres.2005.06.014. Epub 2005 Aug 2. Leuk Res. 2006. PMID: 16081156 No abstract available.

5

Anti-angiogenic effect of bortezomib in patients with multiple myeloma.

Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley JF, Rahemtulla A. Politou M, et al. Among authors: rahemtulla a. Acta Haematol. 2005;114(3):170-3. doi: 10.1159/000087894. Acta Haematol. 2005. PMID: 16227683 No abstract available.

6

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A. Auner HW, et al. Among authors: rahemtulla a. Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4. Leuk Lymphoma. 2013. PMID: 23387937

7

The role of markers of bone remodeling in multiple myeloma.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: rahemtulla a. Blood Rev. 2005 May;19(3):125-42. doi: 10.1016/j.blre.2004.06.001. Blood Rev. 2005. PMID: 15748961 Review.

8

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: rahemtulla a. J Cancer Res Clin Oncol. 2004 Oct;130(10):623-5. doi: 10.1007/s00432-004-0593-4. Epub 2004 Jul 28. J Cancer Res Clin Oncol. 2004. PMID: 15449188

9

Bisphosphonate treatment for multiple myeloma.

Terpos E, Rahemtulla A. Terpos E, et al. Among authors: rahemtulla a. Drugs Today (Barc). 2004 Jan;40(1):29-40. doi: 10.1358/dot.2004.40.1.799436. Drugs Today (Barc). 2004. PMID: 14988768 Review.

10

New insights into the pathophysiology and management of bone disease in multiple myeloma.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: rahemtulla a. Br J Haematol. 2003 Dec;123(5):758-69. doi: 10.1046/j.1365-2141.2003.04712.x. Br J Haematol. 2003. PMID: 14632767 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results